Archive

« Older Entries Newer Entries »

Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation i... Wednesday, November 16th, 2016
HALLE (SAALE), Germany, 16 November 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today the first r [...]
Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies Tuesday, November 15th, 2016
European Patent Office Dismisses Arguments by Regeneron   Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus [...]
Wireless brain-spine connection to overcome paralysis Friday, November 11th, 2016
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating [...]
Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel Im... Wednesday, November 9th, 2016
UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today [...]
Merus strengthens Executive Management Team with the appointment of John Crowley as Chief Financial Officer Thursday, November 3rd, 2016
UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of [...]
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer Wednesday, October 26th, 2016
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of [...]
Curetis Announces Positive Top Line Data from U.S. FDA Trial Tuesday, October 25th, 2016
Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average sensitivity of 90.2% and overall weighted average specificity of 99.3% U.S. FDA submission being [...]
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership wi... Thursday, October 20th, 2016
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company r [...]
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares Thursday, October 6th, 2016
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA   Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares   HALLE/ [...]
Immunic acquires 4SC’s Immunology Portfolio Wednesday, September 28th, 2016
Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases   IMU-838: New oral treatment option for Crohn’s disease [...]

« Older Entries Newer Entries »

2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries Newer Entries »

Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation... Wednesday, November 16th, 2016
HALLE (SAALE), Germany, 16 November 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today the first r [...]
Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies Tuesday, November 15th, 2016
European Patent Office Dismisses Arguments by Regeneron   Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus [...]
Wireless brain-spine connection to overcome paralysis Friday, November 11th, 2016
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating [...]
Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel ... Wednesday, November 9th, 2016
UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today [...]
Merus strengthens Executive Management Team with the appointment of John Crowley as Chief Financial Officer Thursday, November 3rd, 2016
UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of [...]
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer Wednesday, October 26th, 2016
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of [...]
Curetis Announces Positive Top Line Data from U.S. FDA Trial Tuesday, October 25th, 2016
Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average sensitivity of 90.2% and overall weighted average specificity of 99.3% U.S. FDA submission being [...]
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership ... Thursday, October 20th, 2016
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company r [...]
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares Thursday, October 6th, 2016
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA   Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares   HALLE/ [...]
Immunic acquires 4SC’s Immunology Portfolio Wednesday, September 28th, 2016
Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases   IMU-838: New oral treatment option for Crohn’s disease [...]

« Older Entries Newer Entries »

2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview